|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6291161B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
GB8918616D0
(en)
|
1989-08-15 |
1989-09-27 |
Univ Glasgow |
Herpes simplex virus type 1 mutant
|
|
JP3257675B2
(ja)
|
1990-10-12 |
2002-02-18 |
マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． |
修飾リボザイム
|
|
HU215180B
(hu)
|
1992-01-23 |
1998-10-28 |
Merck Patent Gmbh. |
Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
|
|
US5652094A
(en)
|
1992-01-31 |
1997-07-29 |
University Of Montreal |
Nucleozymes
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US6972193B1
(en)
|
1993-02-12 |
2005-12-06 |
Board Of Trustees Of Leland Stanford Junior University |
Regulated transcription of targeted genes and other biological events
|
|
CZ206195A3
(en)
|
1993-02-12 |
1996-04-17 |
Univ Leland Stanford Junior |
Controlled transcription of target genes and other biological materials
|
|
ES2229236T3
(es)
|
1994-01-11 |
2005-04-16 |
Dyax Corporation |
Inhibidores de la plasmina humana derivados de los dominios de kunitz.
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
GB9415319D0
(en)
|
1994-07-29 |
1994-09-21 |
Medical Res Council |
HSV viral vector
|
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6093570A
(en)
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
AU8605598A
(en)
|
1997-07-31 |
1999-02-22 |
University Of Pittsburgh |
Targeted hsv vectors
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
CA2318402A1
(en)
|
1998-01-15 |
1999-07-22 |
Ariad Gene Therapeutics, Inc. |
Regulation of biological events using multimeric chimeric proteins
|
|
AU766513B2
(en)
|
1998-02-13 |
2003-10-16 |
Board Of Trustees Of The Leland Stanford Junior University |
Novel dimerizing agents, their production and use
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
FR2777909B1
(fr)
|
1998-04-24 |
2002-08-02 |
Pasteur Institut |
Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
|
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Life Technologies Corporation |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6692736B2
(en)
|
2000-03-24 |
2004-02-17 |
Cell Genesys, Inc. |
Cell-specific adenovirus vectors comprising an internal ribosome entry site
|
|
NZ522840A
(en)
|
2000-06-01 |
2004-12-24 |
Univ North Carolina |
A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
|
|
ATE452972T1
(de)
|
2001-05-01 |
2010-01-15 |
Ca Nat Research Council |
Induzierbares expressionssystem in eukaryotischen zellen
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
FR2872170B1
(fr)
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
|
EP1828390B1
(en)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
CN103555733A
(zh)
|
2005-01-05 |
2014-02-05 |
F-星生物技术研究与开发有限公司 |
分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
|
|
GB0504767D0
(en)
|
2005-03-08 |
2005-04-13 |
Ares Trading Sa |
Lipocalin protein
|
|
EP1829895A1
(en)
|
2006-03-03 |
2007-09-05 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
|
|
WO2010062966A2
(en)
|
2008-11-26 |
2010-06-03 |
The General Hospital Corporation |
Methods for inducing mixed chimerism
|
|
EP2396343B1
(en)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
ES2683695T3
(es)
|
2010-01-12 |
2018-09-27 |
The University Of North Carolina At Chapel Hill |
Repeticiones terminales invertidas restrictivas para vectores virales
|
|
CA2788682C
(en)
|
2010-02-05 |
2019-03-05 |
The University Of North Carolina At Chapel Hill |
Compositions and methods for enhanced parvovirus transduction
|
|
WO2011146862A1
(en)
|
2010-05-21 |
2011-11-24 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing selective apoptosis
|
|
ES2791716T3
(es)
|
2010-12-14 |
2020-11-05 |
Univ Maryland |
Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer
|
|
EP3470431A1
(en)
|
2012-09-27 |
2019-04-17 |
Merus N.V. |
Bispecific igg antibodies as t cell engagers
|
|
EP4303232A3
(en)
|
2013-02-15 |
2024-04-17 |
The Regents of The University of California |
Chimeric antigen receptor and methods of use thereof
|
|
EP3447072A3
(en)
|
2013-03-05 |
2019-05-22 |
Baylor College of Medicine |
Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
|
|
EP2964253A1
(en)
|
2013-03-05 |
2016-01-13 |
Baylor College Of Medicine |
Heparanase expression in human t lymphocytes
|
|
WO2015017214A1
(en)
|
2013-07-29 |
2015-02-05 |
Bluebird Bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
US20170081411A1
(en)
*
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3288974B1
(en)
|
2015-05-01 |
2020-11-04 |
Inhibrx, Inc. |
Type iii secretion system targeting molecules
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP3341410B1
(en)
|
2015-08-24 |
2021-06-02 |
Cellectis |
Chimeric antigen receptors with integrated controllable functions
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
MX2018010924A
(es)
|
2016-03-11 |
2019-02-13 |
Bluebird Bio Inc |
Células efectoras inmunitarias con edición genómica.
|
|
WO2017180993A1
(en)
|
2016-04-14 |
2017-10-19 |
Bluebird Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
WO2018127585A1
(en)
*
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
AU2018385699B2
(en)
|
2017-12-14 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Daric interleukin receptors
|
|
MA51158A
(fr)
|
2017-12-14 |
2020-10-21 |
Bluebird Bio Inc |
Récepteurs daric nkg2d
|
|
JP7060084B2
(ja)
|
2018-03-26 |
2022-04-26 |
三菱マテリアル株式会社 |
絶縁回路基板用接合体の製造方法および絶縁回路基板用接合体
|
|
US12097219B2
(en)
|
2018-09-10 |
2024-09-24 |
Legend Biotech Ireland Limited |
Single-domain antibodies against CLL1 and constructs thereof
|
|
CA3121478A1
(en)
|
2018-11-30 |
2020-06-04 |
Aleta Biotherapeutics Inc. |
Single domain antibodies against cll-1
|
|
AU2019397152A1
(en)
|
2018-12-14 |
2021-06-24 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020123938A1
(en)
|
2018-12-14 |
2020-06-18 |
Bluebird Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US20240034768A1
(en)
|
2018-12-14 |
2024-02-01 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US12291560B2
(en)
|
2018-12-14 |
2025-05-06 |
Regeneron Pharmaceuticals, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
CA3126422A1
(en)
|
2019-01-14 |
2020-07-23 |
Nanjing Legend Biotech Co., Ltd. |
Chimeric receptor polypeptides and uses thereof
|
|
EP3714941A1
(en)
|
2019-03-27 |
2020-09-30 |
Medigene Immunotherapies GmbH |
Mage-a4 tcrs
|
|
KR20220004751A
(ko)
|
2019-05-04 |
2022-01-11 |
인히브릭스, 인크. |
CLEC12a 결합 폴리펩타이드 및 이의 용도
|
|
CA3139512A1
(en)
|
2019-05-08 |
2020-11-12 |
Inhibrx, Inc. |
Cd123 targeted immunotherapies
|
|
US12421315B2
(en)
|
2019-05-08 |
2025-09-23 |
Regeneron Pharmaceuticals, Inc. |
CLL-1 targeted immunotherapies
|
|
MX2022000896A
(es)
|
2019-07-24 |
2022-02-14 |
Regeneron Pharma |
Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
|
|
CA3154287A1
(en)
|
2019-09-12 |
2021-03-18 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
AU2020359530A1
(en)
|
2019-09-30 |
2022-05-19 |
2Seventy Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2021207613A1
(en)
|
2020-04-10 |
2021-10-14 |
2Seventy Bio, Inc. |
Frb antibodies
|